Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Short term Debt (2018 - 2019)

10x Genomics' Short term Debt history spans 2 years, with the latest figure at $9.9 million for Q4 2019.

  • For Q4 2019, Short term Debt rose 136.02% year-over-year to $9.9 million; the TTM value through Dec 2019 reached $9.9 million, up 136.02%, while the annual FY2019 figure was $9.9 million, 136.02% up from the prior year.
  • Short term Debt for Q4 2019 was $9.9 million at 10x Genomics, up from $7.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $9.9 million in Q4 2019 and bottomed at $4.2 million in Q4 2018.